Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.52 |
| ▸ | GPR139 | Q6DWJ6 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30202951 | 0.84 | ACACB (0.63) | PDE2AACACB | |
| SCHEMBL30186632 | 0.84 | ACACB (0.63) | PDE2AACACB | |
| SCHEMBL17193733 | 0.81 | ACACB (0.59) | ALDH1A1ACACB | |
| SCHEMBL17193732 | 0.81 | ACACB (0.59) | ALDH1A1ACACB | |
| SCHEMBL25837685 | 0.81 | ACACB (0.58) | PDE2AGPR139ALDH1A1ACACB | |
| SCHEMBL23194528 | 0.80 | PDE2A (0.50) | PDE2AGPR139 | |
| SCHEMBL23122640 | 0.79 | GPR139 (0.53) | GPR139ALDH1A1 | |
| SCHEMBL23122643 | 0.79 | GPR139 (0.53) | GPR139ALDH1A1 | |
| SCHEMBL29178120 | 0.79 | ALDH1A1 (0.54) | GPR139ALDH1A1 | |
| SCHEMBL24494666 | 0.79 | ACACB (0.51) | PDE2AGPR139ALDH1A1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146635-A1 | SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST | Takeda Pharmaceutical Company Limited (JP) | 2023-03-15 | — | — | EP | claimed |
| US-20230227416-A1 | SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-20 | — | — | US | disclosed |
| US-20230227416-A1 | SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227416-A1 | SUBSTITUTED BENZOTRIAZINONE METABOLITES OF A GPR139 AGONIST | GPR139, GPR84, GPR3 | PDE2A 1096/4885GPR139 1/4885ALDH1A1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.